Edenlux plans U.S. launch for Eyeary eye-training device

South Korea-headquartered startup Edenlux is preparing to launch its second wellness device, Eyeary, in the U.S. market. The company plans to debut the daily visual recovery tool via the crowdfunding platform Indiegogo around the end of March. This move marks an expansion of the company’s footprint from Asia, where it previously launched its first device, Otus, in 2022 across South Korea, Singapore, Japan, and Taiwan. The expansion aims to address eye health issues caused by digital device overuse, particularly as average daily smartphone use exceeds three hours and total screen time for many adults climbs to six hours or more.

Edenlux products fall under the FDA’s wellness category, which is a classification for products that are not medical devices. This classification allows the company to describe its products for vision training and general eye health. The technology targets the ciliary muscle, which controls the lens inside the eye. According to Edenlux founder and CEO Sungyong Park, when people are young, the muscle is strong enough to focus, but constant smartphone use keeps it contracted, which can weaken it over time and lead to fatigue and vision problems. The device is designed to mitigate common digital eye issues, including “dry and irritated eyes, eye fatigue, blurred vision, headaches, and the worsening of nearsightedness.”

To train these eye muscles, Eyeary uses a lens system featuring 144 focal points, a significant increase from the five diopter focal points in the Otus device. The training is intended to help users recover their visual focus. Park, the Edenlux founder and CEO, stated: “With Otus, users typically took about 12 months to reduce their dependence on reading glasses. Eyeary could shorten that to around six months.”

To support its expansion into the U.S. market, Edenlux has established a U.S. subsidiary in Dallas, Texas, where its devices will undergo final assembly. The expansion builds on the commercial track record of Otus, which has generated $10 million in cumulative revenue.

The company’s growth has been backed by significant venture capital. Edenlux’s funding history includes:

• A $39 million Series A funding round in 2020
• A $60 million Series B funding round in 2022

While Edenlux currently develops and manufactures its devices, it is exploring potential partnerships with major technology firms, including Apple and Samsung, to integrate its vision-protecting technology directly into smartphones.

Why it matters

Edenlux is moving from an Asian-market focus to the U.S., positioning its eye-health hardware as a consumer wellness tool rather than a medical device to address the growing prevalence of digital eye strain.